Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2013, Article ID 183134, 5 pages
http://dx.doi.org/10.1155/2013/183134
Case Report

Peripheral T-Cell Lymphoma with Aberrant Expression of CD19, CD20, and CD79a: Case Report and Literature Review

Department of Pathology & Laboratory Medicine, Chandler Medical Center, College of Medicine, University of Kentucky, 800 Rose Street, Lexington, KY 40536-0298, USA

Received 6 June 2013; Accepted 31 July 2013

Academic Editors: D. J. Allsup, E. Bissé, and D. Galanakis

Copyright © 2013 Rahul G. Matnani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Tisone, J. T. Brandt, J. E. Bohman, and K. S. Theil, “Aberrant expression of CD19 as a marker of monocytic lineage in acute myelogenous leukemia,” American Journal of Clinical Pathology, vol. 107, no. 3, pp. 283–291, 1997. View at Google Scholar · View at Scopus
  2. K. Walter, P. N. Cockerill, R. Barlow et al., “Aberrant expression of CD19 in AML with t(8;21) involves a poised chromatin structure and PAX5,” Oncogene, vol. 29, no. 20, pp. 2927–2937, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Rizzo, M. Stetler-Stevenson, W. Wilson, and C. M. Yuan, “Novel CD19 expression in a peripheral T cell lymphoma: a flow cytometry case report with morphologic correlation,” Cytometry B, vol. 76, no. 2, pp. 142–149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. P. J. Macardle and I. C. Nicholson, “CD20,” Journal of Biological Regulators and Homeostatic Agents, vol. 16, no. 2, pp. 136–138, 2002. View at Google Scholar · View at Scopus
  5. T. W. Kuijpers, R. J. Bende, P. A. Baars et al., “CD20 deficiency in humans results in impaired T cell-independent antibody responses,” Journal of Clinical Investigation, vol. 120, no. 1, pp. 214–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K. U. Chow, W. D. Sommerlad, S. Boehrer et al., “Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases,” Haematologica, vol. 87, no. 1, pp. 33–43, 2002. View at Google Scholar · View at Scopus
  7. K. Yu, Y. Hu, Y. Tan et al., “Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene,” Leukemia & Lymphoma, vol. 49, no. 7, pp. 1368–1373, 2008. View at Google Scholar
  8. C. L. Buckner, L. R. Christiansen, D. Bourgeois, J. J. Lazarchick, and J. Lazarchick, “CD20 positive T-cell lymphoma/leukemia: a rare entity with potential diagnostic pitfalls,” Annals of Clinical and Laboratory Science, vol. 37, no. 3, pp. 263–267, 2007. View at Google Scholar · View at Scopus
  9. R. L. Mohrmann and D. A. Arber, “CD20-positive peripheral T-cell lymphoma: report of a case after nodular sclerosis Hodgkin's disease and review of the literature,” Modern Pathology, vol. 13, no. 11, pp. 1244–1252, 2000. View at Google Scholar · View at Scopus
  10. L. Quintanilla-Martinez, F. Preffer, D. Rubin, J. A. Ferry, and N. L. Harris, “CD20+ T-cell lymphoma: neoplastic transformation of a normal T-cell subset,” American Journal of Clinical Pathology, vol. 102, no. 4, pp. 483–489, 1994. View at Google Scholar · View at Scopus
  11. E. Moriyama, T. Yokose, T. Kodama et al., “Low-grade B-cell lymphoma of mucosa-associated lymphoid tissue in the thymus of a patient with pulmonary amyloid nodules,” Japanese Journal of Clinical Oncology, vol. 30, no. 8, pp. 349–353, 2000. View at Google Scholar · View at Scopus
  12. A. Takami, M. Saito, S. Nakao et al., “CD20-positive T-cell chronic lymphocytic leukaemia,” British Journal of Haematology, vol. 102, no. 5, pp. 1327–1329, 1998. View at Google Scholar · View at Scopus
  13. N. N. Balmer, L. Hughey, K. J. Busam, V. Reddy, and A. A. Andea, “Primary cutaneous peripheral t-cell lymphoma with aberrant coexpression of CD20: case report and review of the literature,” American Journal of Dermatopathology, vol. 31, no. 2, pp. 187–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Buccheri, B. Mihaljevic, E. Matutes, M. J. S. Dyer, D. Y. Mason, and D. Catovsky, “mb-1: a new marker for B-lineage lymphoblastic leukemia,” Blood, vol. 82, no. 3, pp. 853–857, 1993. View at Google Scholar · View at Scopus
  15. E. Pilozzi, K. Pulford, M. Jones et al., “Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma,” The Journal of Pathology, vol. 186, no. 2, pp. 140–143, 1998. View at Google Scholar
  16. R. Lai, J. Juco, S. F. Lee, S. Nahirniak, and W. S. Etches, “Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias,” American Journal of Clinical Pathology, vol. 113, no. 6, pp. 823–830, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Hashimoto, Y. Yamashita, and N. Mori, “Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias,” Journal of Pathology, vol. 197, no. 3, pp. 341–347, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Yao, J. Teruya-Feldstein, M. Raffeld, L. Sorbara, and E. S. Jaffe, “Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall,” Modern Pathology, vol. 14, no. 2, pp. 105–110, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Cobaleda, A. Schebesta, A. Delogu, and M. Busslinger, “Pax5: the guardian of B cell identity and function,” Nature Immunology, vol. 8, no. 5, pp. 463–470, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. H. C. Hollingsworth, M. Stetler-Stevenson, D. Gagneten, D. W. Kingma, M. Raffeld, and E. S. Jaffe, “Immunodeficiency-associated malignant lymphoma: three cases showing genotypic evidence of both T- and B-cell lineages,” American Journal of Surgical Pathology, vol. 18, no. 11, pp. 1092–1101, 1994. View at Google Scholar · View at Scopus
  21. D. M. Knowles, “Molecular pathology of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma,” Seminars in Diagnostic Pathology, vol. 14, no. 1, pp. 67–82, 1997. View at Google Scholar · View at Scopus
  22. E. K. Waller, M. Ziemianska, C. D. Bangs, M. Cleary, I. Weissman, and O. W. Kamel, “Characterization of posttransplant lymphomas that express T-cell- associated markers: immunophenotypes, molecular genetics, cytogenetics, and heterotransplantation in severe combined immunodeficient mice,” Blood, vol. 82, no. 1, pp. 247–261, 1993. View at Google Scholar · View at Scopus
  23. B. Arnulf, C. Copie-Bergman, M.-H. Delfau-Larue et al., “Nonhepatosplenic γδ T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization,” Blood, vol. 91, no. 5, pp. 1723–1731, 1998. View at Google Scholar · View at Scopus
  24. C. B. Cooke, L. Krenacs, M. Stetler-Stevenson et al., “Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic γδ T-cell origin,” Blood, vol. 88, no. 11, pp. 4265–4274, 1996. View at Google Scholar · View at Scopus